In this series, we explore the impact of data from the National Genomic Research Library and highlight opportunities for researchers. In this blog, ...

In a safety review, the FDA identified 14 cases of seizures linked to vitamin B6 deficiency in patients taking carbidopa/levodopa-containing drugs.

Future treatment resistance to focal epilepsy therapy was significantly more likely in individuals who reported suicidal ...

Shares of Xenon Pharmaceuticals (XENE) have gained approximately 20% over the past three months, primarily driven by positive top-line data from the X-TOLE2 study evaluating its lead candidate, ...

This morning on “The Rhode Show” we welcomed Dr. Preeti Gupta, a board-certified neurologist specializing in epilepsy, and the Founder of the NeuroLogic Center for Seizures + Epilepsy.

A large cohort study sheds new light on neurodevelopmental risk in children after prenatal antiseizure medication exposure, ...

Ovid stock surged 18% following positive Phase 1 data for OV329, and investors are getting excited about a forthcoming Phase 2.

In A Nutshell Researchers used computer modeling and physics-based math to calculate the minimum antibiotic and moisturizer doses needed to push severe eczema into remission and keep it there. The ...

Despite trying antidepressants and CBT, the “panic” episodes only worsened, especially in the three years before the test.

Sheffield Children’s NHS Foundation Trust has become the first site in Europe to recruit a patient to a major international clinical trial investigating a potential new treatment for a severe form of ...

Ovid Therapeutics (OVID) shares jumped over 40% premarket as the biopharmaceutical company reported favorable safety and tolerability results for the 7 mg dose of its OV329 epilepsy drug, while ...

The 7 mg dose of OV329 demonstrated favorable safety and tolerability profile, reinforcing best-in-category potential for ...